EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Pancreatic cancer screening is effective in individuals at risk with predisposing germline gene variants, but not in gene variant‐negative familial pancreatic cancer families

Elisabeth Maurer iD, Bettina Lehman, Elvira Matthäi, Ulrike Denzer, Jens Figiel, Moritz Jesinghaus, Emily P Slater, Ulrich Stefenelli, Thomas M Gress, Detlef K Bartsch

United European Gastroenterology Journal · 2024

DOI: 10.1002/ueg2.12631 ↗

Kurz gefasst

Fachartikel in der Zeitschrift United European Gastroenterology Journal, 2024. Verfasst von Elisabeth Maurer und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Visceral-, Thoracic- and Vascular Surgery, Philipps University Marburg, Marburg, Germany. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Early Detection of Cancer, Genetic Predisposition to Disease, Germ-Line Mutation. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Deutsche Krebshilfe.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the diagnostic yield of pancreatic cancer screening in individuals at risk (IAR) from familial pancreatic cancer (FPC) families with respect to the presence or absence of pathogenic germline variants predisposing to pancreatic adenocarcinoma (PDAC).

Design

In a 20 years period, IAR from FPC families were enrolled in a prospective screening program of the national case collection for FPC of Germany, including magnet resonance imaging (MRI) and endoscopic ultrasound (EUS). The diagnostic yield was analyzed regarding significant pancreatic lesions such as PDAC, high‐grade pancreatic‐intraepithelial‐neoplasia (PanIN3) and intraductal‐papillary‐mucinous‐neoplasia (IPMN) with high‐grade dysplasia. Screening results were compared between carriers of pathogenic variants and variant‐negative IAR.

Results

337 IAR, including 74 (22%) variant‐carriers and 263 IAR of variant‐negative FPC families (mean age 49; standard deviation [SD] + 8.9) were followed 64 (SD + 55) months. IAR underwent 5.1 (SD + 3.9) screening visits with 1733 MRI (5.1,SD + 3.9 per IAR) and 728 EUS (2.2,SD + 1.7 per IAR). In 12 (4%) cases, significant pancreatic lesions were detected, including 4 PDAC, 3 PanIN3 and 5 high‐grade IPMN. Three of 4 IAR with PDAC died after a mean of 27 months postoperatively, and one IAR is alive without evidence of disease after 31 months. The diagnostic yield for significant lesions was 13.5% (10/74) for variant carriers compared to 0.8% (2/263) for IAR of variant‐negative FPC families ( p < 0.001). Logistic regression analysis revealed that a negative variant status was almost always accompanied by the absence of a significant lesion over time with a negative predictive value of 99.2% (95% CI 97.3%–99.9%).

Conclusion

The diagnostic yield seems to justify PDAC screening in IAR of FPC‐families with pathogenic germline variants in PDAC predisposing genes, not in IAR of variant‐negative families.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsEarly Detection of CancerGenetic Predisposition to DiseaseGerm-Line MutationMagnetic Resonance ImagingEndosonographyHumansMaleFemaleMiddle AgedGermanyAdultProspective StudiesCarcinoma, Pancreatic DuctalAgedAdenocarcinomaRisk FactorsCarcinoma

Stichwörter der Autor:innen

IPMNPDACadenocarcinomadiagnosisfamiliargenetichighincreasedintraepithelialneoplasia

Autor:innen und Institutionen

  • Department of Visceral-, Thoracic- and Vascular Surgery, Philipps University Marburg, Marburg, Germany.
  • Department of Gastroenterology, Endocrinology, Metabolism and Infectiology, Philipps University Marburg, Marburg, Germany.
  • Department of Diagnostic and Interventional Radiology, Philipps University Marburg, Marburg, Germany.
  • Institute of Pathology, Philipps University Marburg, Marburg, Germany.
  • Data and Statistics Dr. Ulrich Stefenelli, Würzburg, Germany.

ORCID-Profile: Elisabeth Maurer

Förderung

  • Deutsche Krebshilfe

Zitieren

APA

Maurer, E., Lehman, B., Matthäi, E., Denzer, U., Figiel, J., Jesinghaus, M., Slater, E. P., Stefenelli, U., Gress, T. M., & Bartsch, D. K. (2024). Pancreatic cancer screening is effective in individuals at risk with predisposing germline gene variants, but not in gene variant‐negative familial pancreatic cancer families. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.12631

Vancouver

Maurer E, Lehman B, Matthäi E, Denzer U, Figiel J, Jesinghaus M, et al. Pancreatic cancer screening is effective in individuals at risk with predisposing germline gene variants, but not in gene variant‐negative familial pancreatic cancer families. United European Gastroenterology Journal. 2024. doi:10.1002/ueg2.12631

BibTeX
@article{Maurer2024,
  author = {Maurer, Elisabeth and Lehman, Bettina and Matthäi, Elvira and Denzer, Ulrike and Figiel, Jens and Jesinghaus, Moritz and Slater, Emily P and Stefenelli, Ulrich and Gress, Thomas M and Bartsch, Detlef K},
  title = {Pancreatic cancer screening is effective in individuals at risk with predisposing germline gene variants, but not in gene variant‐negative familial pancreatic cancer families},
  journal = {United European Gastroenterology Journal},
  year = {2024},
  doi = {10.1002/ueg2.12631}
}
Kostenlos starten →